Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk

#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p

Are we asking women with IPAF about family planning? Abstract #0944 #ACR22 @RheumNow 🫁 31 women 🤰83% had RF for adverse pregnancy outcomes 👼1/3 women had family plan. or birth control talks with pulm. docs ✋>50% women who saw a rheumatologist discussed these topics

Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV

Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK

#abst2109 #ACR22 @RheumNow GO-VIBRANT bio-naïve pts w/active PsA Rx w/IV GLM tend respond slower in all domains if ⬆️ age, HAQ-DI score, and spinal pain; smoking gives w/lower odds of HAQ-DI ≤0.5 at W52. minimal SJC& ⬇️enthesitis achieved significantly faster than TJC, HAQ-DI https://t.co/qqmjEAq3Cd

#ACR22 Abstr#L08 Is Evusheld effective in the first 6 mths of therapy in #COVID Omicron era? A cohort study of 157 RMD patients who were fully vaccinated reported 24 (15%) breakthrough infection; only 2 (1%) required hospitalisation. COVID occurred ~3mths post-therapy @RheumNow https://t.co/VJogB2otbn

Possible new biomarker in early RA? RA patients with high level of measurable fibrogenesis (PRO-C3 serum levels) less likely to respond to TCZ, as compared to patients with low level of fibrogenesis. Abs 1986 #ACR22 @RheumNow https://t.co/xnyoV2xbWq https://t.co/Vka8UZsrar

@RheumNow #ACR22 https://t.co/dO7xDTApqP

Immunosuppressants (eg. MTX, RTX, MMF) can reduce immunogenicity to vaccines. VACIMRA study showing no difference in disease activity (beyond 1 month) and damage when MTX initiation was delayed by 1 month for the PCV13 pneumococcal vaccine. @RheumNow ABST1960 #ACR22 https://t.co/SKQ2qx3lJG